Transdermal drug delivery system is defined as self-contained, discrete dosage form which when applied to intact skin deliver the drug through the intact skin at a controlled rate to the systemic circulation and maintain the drug concentration within the therapeutic window for a prolonged period of time. Recently, the use of transdermal patches for pharmaceuticals is limited because only a few drugs have proven to be effectively delivered through the skin. TDDS is the alternative route of administration for the patients who cannot tolerate oral dosage forms such as vomiting patient.
The Global Transdermal Drug Delivery Systems Market was valued at $ XX Mn in 2018 and is forecast to grow at XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The rise in geriatric population and upsurge in a number of patients suffering from chronic disorders are expected to drive the market growth. Moreover, the increase in adoption of third-generation transdermal drug delivery systems, such as iontophoresis, boosts the market growth. However, the disadvantages of these delivery systems, such as irritation at the site of application and edema, are expected to impede the market growth. According to a CADI Research Foundation, hypertension is the most prevalent disease in India. It is evident from the fact that the number of people with hypertension is projected to increase to 214 million in 2025 from 118 million in 2000.
Transdermal Drug Delivery Systems depending on the Type, matrix patch segment is expected to account for the largest share of the Transdermal Drug Delivery Systems market. The matrix patch incorporates the drug into an adhesive polymer matrix, from which the drug is continuously released into the skin. The dose of drug delivered depends on the amount of drug held in the matrix and the area of the patch applied to the skin.
The global Transdermal Drug Delivery Systems Market is segmented on the basis of Type, Indication, End-user, and region.
Based on the Type: Transdermal Patches and Transdermal Semisolids.
Based on the Indication:Hormonal disorder, Cardiac disorder, Migraine, Parkinson Disease, Alzheimer’s, HIV, Osteoporosis, Dermatological disease
Based on End-user: Home Care Settings, Hospitals, and Clinics
Based on the region: North America, Asia-Pacific, Europe, and LAMEA. North America is considered as the biggest market of Transdermal drug delivery systems. Moreover, the presence of main pharmaceutical organizations in these regions has decidedly affected the development of the market. Nations, for example, the US, Canada, Mexico, have represented a solid interest of idiopathic pulmonary fibrosis therapeutics credited to the expanding number of IPF rate happening in these nations.
The report covers in-depth analysis of the Global Transdermal Drug Delivery Systems Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by Type (Transdermal Patches, Transdermal Semisolids). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Transdermal Drug Delivery Systems Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.